What Wegovy is supposed to do — and how it actually does it

The decision most people are quietly weighing up

When someone searches for what Wegovy is supposed to do, they are rarely looking for a pharmacology lecture. They are usually at a decision point: should I try this, is it just an appetite suppressant, will it actually change anything, and is it safe? Those are the right questions. This page works through each of them with straightforward answers drawn from the clinical evidence and UK regulatory guidance.

Start with the framing that matters most. Weight is shaped by biology (hormones, gut signalling, metabolic rate) not purely by willpower. Wegovy is designed to work with that biology rather than against it. That is not marketing language; it is the mechanism the medicine is built around, and understanding it changes how people approach treatment.

A question our prescribers hear most weeks is whether Wegovy is just a short-term fix or something that produces real, lasting change. The honest answer: the evidence shows meaningful weight loss during treatment, and the medicine works best when combined with changes to eating habits and activity. What happens after stopping is a separate clinical conversation, worth having before you start.

You can read about what Wegovy is and how it is made for a deeper background on the medicine itself.

What Wegovy is actually doing inside your body

Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases naturally after eating. It signals to your brain that you have had enough, slows the rate at which your stomach empties, and plays a role in regulating blood sugar. Semaglutide mimics this hormone and keeps those signals active for longer than your body would naturally sustain them.

The practical result is that most people feel genuinely less hungry, find smaller portions satisfying, and think about food less between meals. This is different from older appetite suppressants, which largely worked through stimulant pathways. The NHS semaglutide medicines page explains the mechanism clearly and is worth reading alongside any prescriber conversation.

Wegovy is injected once a week, under the skin of the abdomen, thigh or upper arm, using a pre-filled pen. Treatment begins at a low dose and is titrated upward by the prescriber over several months, reaching a 2.4 mg maintenance dose, or, following the April 2026 MHRA approval, up to 7.2 mg for eligible patients. The titration schedule exists to give your body time to adjust and to reduce the chance of side effects, particularly nausea in the early weeks.

For the specifics of what the medicine contains and how it differs from other semaglutide products, this page on Wegovy's active ingredient covers it clearly.

What the clinical evidence shows, and the honest limits

The STEP 1 trial, published in the New England Journal of Medicine, enrolled around 1,960 adults with obesity or overweight plus at least one weight-related condition. Over 68 weeks, those using semaglutide 2.4 mg alongside lifestyle guidance lost an average of roughly 15% of body weight, compared with around 2.4% in the placebo group. That is a substantial difference.

Those figures are averages. Individual results vary depending on starting weight, how closely lifestyle guidance is followed, dose tolerance, and other health factors. Wegovy is not designed for cosmetic weight loss or rapid results; the MHRA is explicit that GLP-1 medicines are not assessed for those purposes. The medicine's licensed purpose is weight management in adults who meet clinical criteria, as part of a broader plan that includes diet and activity.

NICE's appraisal of semaglutide, published as TA875, recommends it within specialist weight management services for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related comorbidity. Private prescribing follows the licensed eligibility criteria in the Wegovy SmPC rather than the NHS commissioning restrictions, so the route you take affects what is available to you.

For more on what to do while you are on Wegovy to get the most from treatment, there is dedicated guidance worth reading before you start.

Side effects, aftercare and where the clinical picture sits

The most common side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, burping, and sometimes fatigue or headache, especially in the weeks after starting or increasing the dose. For most people these settle. They are the body adjusting to the hormone signal being sustained for longer than it naturally would be.

Less common but more serious concerns include gallbladder problems and, in rare cases, pancreatitis. The MHRA has issued specific guidance on recognising pancreatitis symptoms: severe, persistent stomach pain that may spread to the back, with or without vomiting, warrants urgent medical attention. Report any suspected side effect, however minor, through the Yellow Card scheme.

Wegovy is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for under-18s. Your prescriber will go through your full medical history, current medicines and circumstances before anything is approved, and it is also worth familiarising yourself with what not to do on Wegovy so you go into treatment clear on the behaviours and combinations to avoid.

Ongoing support matters as much as the prescription itself. You can find out about the aftercare support available during treatment and what to ask for from your clinical team. If you are thinking about whether treatment might suit you, our page on semaglutide gives useful context on the medicine behind Wegovy, and the free consultation with our prescribers is the right starting point, they will give you a straight answer based on your health picture.